Form 4: Eli Lilly Director Defers Compensation into Stock

Eli Lilly & Co. Director Gabrielle Sulzberger acquired 6.627 shares of common stock by deferring cash compensation, increasing her beneficial ownership to 2,721.97 shares.

Summary

• Director Gabrielle Sulzberger acquired 6.627 shares of Eli Lilly & Co. common stock.
• The acquisition occurred on September 15, 2025, at a price of $748.19 per share.
• These shares were acquired by deferring cash compensation under the Lilly Directors' Deferral Plan.
• The shares will be settled in common stock following her separation from service.
• Following this transaction, Sulzberger beneficially owns 2,721.97 shares of Eli Lilly & Co. common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, even through deferred compensation, generally signals confidence in the company's future prospects and aligns management interests with shareholders. It's a positive, though not extraordinary, event.

Positives

• Director Gabrielle Sulzberger increased her beneficial ownership in Eli Lilly & Co. by acquiring 6.627 shares.
• The acquisition through deferred compensation demonstrates a long-term commitment and alignment of interests with shareholders.

Future Outlook

The acquired shares, deferred as stock units, will be settled in common stock following the reporting person's separation from service, indicating a long-term holding strategy.

Industry Context

This transaction reflects a standard practice for director compensation within the pharmaceutical industry, where equity-based incentives are used to align director interests with long-term company performance.

Comparison to Industry Standards

• The deferral of cash compensation into stock units is a common practice among large-cap pharmaceutical companies, such as Pfizer or Johnson & Johnson, for their non-employee directors.
• This mechanism is designed to foster long-term alignment with shareholder interests, similar to how directors at companies like Merck or AbbVie often receive a significant portion of their compensation in equity.

Related Party Transactions

• Acquisition of 6.627 shares of common stock by Director Gabrielle Sulzberger through the Lilly Directors' Deferral Plan, in lieu of cash compensation.

Stakeholder Impact

• Shareholders: Increased alignment of director's financial interests with long-term shareholder value due to equity ownership.

Next Steps

• Settlement of the acquired stock units into common stock upon Gabrielle Sulzberger's separation from service.

Key Dates

Recommendation

While the director's decision to defer cash compensation into company stock is a positive signal of confidence and aligns interests, this single, routine compensation-related transaction is not sufficient to warrant a 'buy' or 'sell' recommendation. It reinforces a 'hold' position for existing investors, indicating continued insider belief in the company's long-term value.

Keywords

Eli Lilly, LLY, Insider Transaction, Form 4, Director Compensation, Stock Acquisition, Gabrielle Sulzberger, Pharmaceuticals